![Markus Haake](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Markus Haake
Keine laufenden Positionen mehr
Karriereverlauf von Markus Haake
Ehemalige bekannte Positionen von Markus Haake
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Corporate Officer/Principal | - | - |
Ganymed Pharmaceuticals AG
![]() Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Corporate Officer/Principal | - | - |
Kenta Biotech AG
![]() Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2007 | - |
Ausbildung von Markus Haake
University of Dortmund | Undergraduate Degree |
Wuerzburg Schweinfurt University of Applied Sciences | Doctorate Degree |
Statistik
International
Deutschland | 5 |
Schweiz | 2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Kenta Biotech AG
![]() Kenta Biotech AG BiotechnologyHealth Technology Kenta Biotech AG engages in the research, development, production, and marketing of biotechnological and pharmaceutical products. It also specializes in the discovery and development of monoclonal antibodies for the treatment of life-threatening hospital infections. The company was founded by Alois B. Lang on February 9, 2006 and is headquartered in Zug, Switzerland. | Health Technology |
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
Ganymed Pharmaceuticals AG
![]() Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Health Technology |
- Börse
- Insiders
- Markus Haake
- Erfahrung